Drugs / Align Probiotic
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04175392 Comparator | Jan 2021 → Mar 2022 | cirrhosis of liver, fibrotic liver disease, metabolic dysfunction-associated steatohepatitis | Corewell Health East | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Align Probiotic | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04175392 ↗ |
| Modality | Other / unclassified | “probiotics, a beneficial intestinal bacteria supplement” NCT04175392 ↗ |
| Route | Oral | “daily oral intake of supplement” NCT04175392 ↗ |